M Farnier Selected Research

M Farnier Research Topics

5	Hypercholesterolemia 02/2011 - 01/2000
3	Dyslipidemias (Dyslipidemia) 02/2018 - 02/2001
3	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 02/2018 - 02/2011
2	Cardiovascular Diseases (Cardiovascular Disease) 05/2014 - 02/2011
2	Abdominal Obesity 12/2007 - 12/2007
2	Insulin Resistance 12/2007 - 09/2001
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2006 - 09/2001
1	Coronary Artery Disease (Coronary Atherosclerosis) 02/2018
1	Xanthomatosis (Xanthoma) 02/2018
1	Heart Diseases (Heart Disease) 10/2006
1	Body Weight (Weight, Body) 10/2001
1	Type 2 Diabetes Mellitus (MODY) 09/2001
1	Overweight 09/2001
1	Weight Loss (Weight Reduction) 09/2001
1	Hypertension (High Blood Pressure) 09/2001
1	Dementia (Dementias) 05/2001
1	Stroke (Strokes) 05/2001
1	Bone Resorption 04/2001
1	3 Autosomal Dominant Hypercholesterolemia 08/2000
1	Hyperlipidemias (Hyperlipidemia) 01/2000

4	CholesterolIBA 02/2018 - 01/2000
3	LDL Lipoproteins (beta Lipoproteins)IBA 02/2018 - 01/2000
3	LDL CholesterolIBA 05/2014 - 01/2000
3	LipidsIBA 02/2011 - 09/2001
3	Triglycerides (Triacylglycerol)IBA 12/2007 - 01/2000
3	Atorvastatin (Lipitor)FDA Link 04/2001 - 01/2000
2	HDL CholesterolIBA 12/2007 - 10/2006
2	Simvastatin (Zocor)FDA LinkGeneric 04/2001 - 01/2000
2	Fenofibrate (CiL)FDA LinkGeneric 05/2000 - 01/2000
1	A-factor (Streptomyces)IBA 02/2018
1	ElementsIBA 02/2018
1	LDL Receptors (LDL Receptor)IBA 02/2011
1	Nonesterified Fatty Acids (NEFA)IBA 12/2007
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 12/2007
1	oxidized low density lipoproteinIBA 12/2007
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2001
1	Alkaline PhosphataseIBA 04/2001
1	Biomarkers (Surrogate Marker)IBA 04/2001
1	Collagen Type I (Type I Collagen)IBA 04/2001
1	Biological ProductsIBA 02/2001
1	Apolipoproteins B (ApoB)IBA 08/2000
1	Fluvastatin FDA Link 01/2000
1	Cholesterol Esters (Cholesteryl Esters)IBA 01/2000
1	VLDL LipoproteinsIBA 01/2000